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Background: Papillary muscle rupture (PMR) is a rare, but dramatic mechanical complication of myocardial
infarction (MI), which can lead to rapid clinical deterioration and death. Immediate surgical intervention is
considered the optimal and most rational treatment, despite high risks. In this study we sought to identify
overall long-term survival and its predictors for patients who underwent mitral valve surgery for post-MI PMR.
Methods: Fifty consecutive patients (mean age 64.7 ± 10.8 years) underwent mitral valve repair (n = 10) or
replacement (n = 40) for post-MI PMR from January 1990 through May 2014. Clinical data, echocardiographic
data, catheterization data, and surgical data were stored in a dedicated database. Follow-up was obtained in
June of 2014; mean follow-up was 7.1 ± 6.8 years (range 0.0-22.2 years). Univariate and multivariate Cox proportional
hazard regression analyses were performed to identify predictors of long-term survival. Kaplan-Meier curves were
compared with the log-rank test.
Results: Kaplan-Meier cumulative survival at 1, 5, 10, 15, and 20 years was 71.9 ± 6.4%, 65.1 ± 6.9%, 49.5 ± 7.6%,
36.1 ± 8.0% and 23.7 ± 9.2%, respectively. Univariate and multivariate analyses revealed logistic EuroSCORE ≥40%
and EuroSCORE II ≥25% as strong independent predictors of a lower overall long-term survival. After removal
of the EuroSCOREs from the model, preoperative inotropic drug support and mitral valve replacement (MVR)
without (partial or complete) preservation of the subvalvular apparatus were independent predictors of a lower
overall long-term survival.
Conclusions: Logistic EuroSCORE ≥40%, EuroSCORE II ≥25%, preoperative inotropic drug support and MVR
without (partial or complete) preservation of the subvalvular apparatus are strong independent predictors of a
lower overall long-term survival in patients undergoing mitral valve surgery for post-MI PMR. Whenever possible, the
subvalvular apparatus should be preserved in these patients.
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Table 1 Preoperative patient data (n = 50)
Variablea Value





Class III 7 (14)
Class IV 43 (86)
EuroSCORE I (logistic), % 29.9 ± 22.6
EuroSCORE II, % 19.6 ± 14.5
Previous myocardial infarction 50 (100)
Inferior and/or posterior 34 (68)
Inferoposterolateral 13 (26)
Anterolateral 9 (18)
Coronary artery disease 50 (100)
Left main stenosis 3 (6)
One-vessel disease 24 (48)
Two-vessel disease 18 (36)
Three-vessel disease 8 (16)
Infarct related artery
Left anterior descending coronary artery 1 (2)
Left circumflex coronary artery 29 (58)
Right coronary artery 20 (40)
Previous percutaneous coronary intervention 14 (28)
Previous cardiac surgery 0 (0)
Preoperative grade of mitral regurgitation
3+ (moderate) 1 (2)
4+ (severe) 49 (98)
Preoperative LV function
Normal (EF >50%) 34 (68)
Moderately impaired (EF 30-50%) 11 (22)
Severely impaired (EF <30%) 5 (10)
Heart rhythm
Sinus rhythm 45 (90)
Atrial fibrillation 5 (10)
Pacemaker 0 (0)
Pulmonary artery pressure
Systolic/diastolic, mmHg 45 ± 13/25 ± 10
Mean, mmHg 32 ± 10
Pulmonary capillary wedge pressure, mmHg 24 ± 14
Mechanical ventilation 23 (46)
Inotropic drug support 28 (56)
Intra-aortic balloon pump 23 (46)
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In the current era of early reperfusion with primary per-
cutaneous coronary intervention (PCI) following acute
ST-elevation myocardial infarction (STEMI), the inci-
dence of post-myocardial infarction papillary muscle
rupture (post-MI PMR) has dropped from 1-5% in the
eighties and early nineties to <0.5% in recent years [1-3].
Although rare, PMR is still a dramatic complication,
which can lead to rapid clinical deterioration and death
[1]. Approximately 80% of ruptures occur within 7 days
after MI, but a delayed rupture several weeks or months
after MI is also possible [1,2,4]. The natural history of
post-MI PMR is extremely unfavorable and under med-
ical treatment alone mortality may be as high as 50% in
the first 24 hours (especially when PMR is complete),
and as high as 80% in the first week [4,5].
Since the first mitral valve replacement (MVR) for
post-MI PMR in 1965 [6], several reports have empha-
sized that immediate surgical intervention is the optimal
and most rational treatment for acute PMR, despite high
risks [2,4,7]. Although mitral valve repair may improve
outcome due to a better preservation of postoperative
left ventricular (LV) function [8-13], MVR is generally
preferred in these haemodynamically unstable, high-risk
patients [7,14-18].
In this study we sought to identify overall long-term
survival and its predictors for patients who underwent
mitral valve surgery for post-MI PMR.
Methods
This study was conducted in accordance with the guide-
lines of the University Medical Center Groningen Insti-
tutional Review Board.
Patients
Between January 1990 and May 2014, 50 consecutive pa-
tients underwent mitral valve surgery for moderate-to-
severe (grade 3+) or severe (grade 4+) mitral regurgitation
(MR) caused by post-MI PMR. Clinical data, echocardio-
graphic data, catheterization data, and surgical data were
stored in a dedicated database. Baseline patient characteris-
tics are summarized in Table 1. All patients had a docu-
mented MI before PMR. Infarct location was determined
electrocardiographically and echocardiographically (by the
detection of wall motion abnormalities). Four patients (8%)
had a history of congestive heart failure, 12 patients (24%)
had hypertension, 9 patients (18%) had diabetes mellitus,
16 patients (32%) were smokers, 6 patients (12%) had
hypercholesterolemia, 7 patients (14%) were obese (body
mass index > 30 kg/m2), 2 patients (4%) had peripheral vas-
cular disease, 7 patients (14%) had a family history of
coronary artery disease, 1 patient (2%) had chronic renal
disease, 3 patients (6%) had chronic obstructive pulmonary
disease, and 5 patients (10%) had cerebrovascular disease.
Table 1 Preoperative patient data (n = 50) (Continued)
Serum creatinine, μmol/L 159 ± 94
Acute renal failure 10 (20)
Cardiogenic shock 33 (66)
aData are presented as mean ± standard deviation or number (%).
EF = ejection fraction; LV = left ventricle; NYHA = New York Heart Association.







Timing of mitral valve surgery
Surgery ≤7 days after MI 29 (58)
Surgery >7 days and ≤30 days after MI 9 (18)
Surgery >30 days after MI 12 (24)
Mitral valve replacement 40 (80)
Mechanical prosthesis 36 (90)
Bioprosthesis 4 (10)
Preservation of the SA (partial or complete) 26 (65)
AMVL and attached SA (partial or complete) 5 (19)
PMVL and attached SA (partial or complete) 14 (54)
AMVL and PMVL and attached SA (partial or complete) 7 (27)
Mitral valve repair 10 (20)
Concomitant surgery 28 (56)
Coronary artery bypass grafting 24 (48)
Septal rupture closure 2 (4)
Aortic valve replacement 1 (2)
Tricuspid valve plasty 2 (4)
Duration of surgery, min 278 ± 88
Cardiopulmonary bypass time, min 179 ± 67
Aortic cross-clamp time, min 98 ± 35
Intraoperative IABP requirement 26 (52)
aData are presented as mean ± standard deviation or number (%).
AMVL = anterior mitral valve leaflet; IABP = intra-aortic balloon pump;
MI = myocardial infarction; PMVL = posterior mitral valve leaflet;
SA = subvalvular apparatus.
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All patients underwent preoperative echocardiography
(transthoracic (TTE) and/or transesophageal (TEE)) and
coronary angiography. TTE accurately revealed the diag-
nosis of PMR in 20 patients (40%). PMR was suspected
in the remaining 30 patients (60%) and confirmed with
TEE in 24 patients (48%). In 6 patients (12%) the exact
mechanism of MR remained inconclusive. Left ventricular
function was assessed by echocardiography. In addition,
wall motion abnormalities were documented for infarct
localization.
Surgical technique
Surgical data is summarized in Table 2.
Patients were considered to undergo a salvage operation
when brought to the operating room under cardiopulmo-
nary resuscitation, an emergency operation when brought
to the operating room directly from the catheterization lab
or intensive care unit because of haemodynamic instability,
and an urgent operation when operated on during the
same hospitalization as for angiography because their dis-
charge was deemed medically unreasonable [19]. Other-
wise the operation was considered elective.
PMR was confirmed during surgery in all patients.
When a papillary muscle (PM) was divided into several
heads, rupture of a single head was defined as “partial”
[11,12]. In case of detachment of the main insertion of a
head which still remained fixed to the remnant PM via
muscular bridges, rupture was defined as “incomplete”
[11,12]. Rupture of the whole PM was defined as “total
and complete” [11,12]. Posteromedian papillary muscle
rupture (PMPMR) occurred in 44 patients (88%), antero-
lateral papillary muscle rupture (ALPMR) occurred in 5
patients (10%), and combined complete PMPMR and
ALPMR occurred in 1 patient (2%). Complete PMPMR
occurred in 15 patients (39%), incomplete PMPMR oc-
curred in 2 patients (5%), and partial PMPMR occurred
in 25 patients (57%). Complete ALPMR occured in 4 pa-
tients (80%), incomplete ALPMR did not occur, and partial
ALPMR occurred in 1 patient (20%). Isolated posterior mi-
tral valve leaflet (PMVL) prolapse was found in 15 patients
(30%), isolated anterior mitral valve leaflet (AMVL) pro-
lapse was found in 12 patients (24%), and combined pro-
lapse was found in 23 patients (46%).
Myocardial protection was carried out using mod-
erate systemic hypothermia and antegrade or combinedantegrade and retrograde cardioplegia. The mitral valve
was exposed with a left atriotomy (in 36 patients), with a
transseptal approach (in 13 patients), or with a left
ventriculotomy (in one patient with a ventricular septal
rupture). Surgeon’s choice dictated treatment strategy.
Ten patients underwent mitral valve repair (20%). The
mitral valve was repaired by reimplantation of the PM in
the LV wall combined with an annuloplasty ring in 1 pa-
tient, by reimplantation of the PM in the corresponding
PM with a sandwiched pledget-reinforced polytetrafluor-
ethylene (PTFE) suture combined with an annuloplasty
ring in 2 patients, by quadrangular resection of P2 com-
bined with an annuloplasty ring in 6 patients, and by
commissuroplasty combined with an annuloplasty ring in
1 patient. Mitral valve repair with a quadrangular resection
of P2 combined with an annuloplasty ring failed intraoper-
atively in 1 patient and resulted in MVR. Concomitant
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comitant coronary artery bypass grafting (CABG) was per-
formed in 24 patients (48%) (Table 2). After weaning from
cardiopulmonary bypass mitral valve competence was con-
firmed with TEE.
Patients who underwent mitral valve repair or MVR
with a bioprosthesis received acenocoumarol treatment
for 3 months and patients who underwent MVR with a
mechanical prosthesis were put on lifelong acenocou-
marol treatment. In addition, patients who underwent
concomitant CABG also received lifelong acetylsalicylic
acid treatment.Follow-up
Follow-up was obtained in June of 2014 directly from
outpatient visits or by telephone interview with the
patient and/or the referring physician. No patient was
lost to follow-up. Overall long-term mortality was de-
fined as death of any cause after surgery (and included
in-hospital deaths).Figure 1 Kaplan-Meier actuarial overall long-term survival after
mitral valve surgery for post-MI PMR. Pts = patients; + = censored.Statistics
Continuous variables were expressed as mean ± standard
deviation. Categorical variables were expressed as
percentages.
Cox proportional-hazard regression analysis was used
to determine univariate predictors and multivariate
independent predictors of overall long-term survival.
Univariate variables with P < 0.10 were included in the
multivariate analysis. Age and gender were included in all
multivariate models, irrespective of the results of univariate
analysis. Multivariate analysis was performed with the lo-
gistic EuroSCORE (continuous variable) (model 1), with
the EuroSCORE II (continuous variable) (model 2), with
logistic EuroSCORE ≥40% (categorical variable) (model 3),
with EuroSCORE II ≥25% (categorical variable) (model 4),
and without the EuroSCOREs (model 5). Multivariate Cox
proportional-hazard regression analysis by means of a for-
ward stepwise algorithm (cutoff for entry and removal set
at a significance level of 0.05) was performed to identify in-
dependent predictors of overall long-term survival. Hazard
ratios were reported with 95% confidence intervals (CI).
Goodness of fit of the final model was assessed with
the Chi square (χ2) goodness-of-fit test (the log likelihood
statistic).
Separate multivariate analyses were performed with a
cutoff value of 40% for the logistic EuroSCORE (model 3)
and a cutoff value of 25% for the EuroSCORE II (model 4).
We have previously shown that these values were optimal
cutoff values in predicting in-hospital mortality [13]. The
EuroSCOREs were included as categorical variables at
these cutoff values to determine if they could also predict
overall long-term survival.Survival curves were calculated and presented accord-
ing to the product-limit method of Kaplan and Meier.
Cumulative survival was expressed as percentage ±
standard error. Survival was expressed as mean ± standard
error. Differences in survival between groups were com-
pared with the log-rank test.
All calculations were performed using a commercially
available statistical package (IBM SPSS Statistics 21.0;
IBM Corporation, Chicago, IL, USA). Statistically signifi-
cant differences were established at P < 0.05.
Results
Overall long-term survival
Mean follow up was 7.1 ± 6.8 years (range: 0.0 to
22.2 years). Total follow-up was 353.1 patient-years.
Actuarial overall long-term survival after mitral valve
surgery for post-MI PMR is shown in Figure 1. Kaplan-
Meier cumulative survival at 1, 5, 10, 15, and 20 years
was 71.9 ± 6.4%, 65.1 ± 6.9%, 49.5 ± 7.6%, 36.1 ± 8.0% and
23.7 ± 9.2%, respectively. Causes of death are shown in
Table 3. At last follow-up all survivors (n = 21) were in
NYHA functional class I or II.
Predictors of overall long-term survival
Univariate and multivariate Cox regression analyses of
long-term survival are shown in Table 4. Multivariate
analysis was performed with the logistic EuroSCORE
(continuous variable) (model 1), with the EuroSCORE II
(continuous variable) (model 2), with logistic Euro-
SCORE ≥40% (categorical variable) (model 3), with
EuroSCORE II ≥25% (categorical variable) (model 4),
and without the EuroSCOREs (model 5).
Table 3 Postoperative patient data (n = 50)
Variable/Conditiona Value
Reoperation for recurrent MR 1 (2)
Causes of death (n = 29)
(End-stage) heart failure 9 (31)
Refractory cardiogenic shock 3 (10)
Haemorrhagic shock (massive bleeding) 2 (7)
Acute myocardial infarction 1 (3)
Arrhythmic sudden death 1 (3)
Septal rupture 1 (3)
Left ventricular rupture 1 (3)
Ruptured aortic aneurysm 1 (3)
Non-cardiac 3 (10)
Unknown 7 (24)
aData are presented as number (%).
MR =mitral regurgitation.
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Multivariate Cox proportional-hazard regression analysis
with the logistic EuroSCORE as a continous variable re-
vealed the logistic EuroSCORE as an independent pre-




Age, y 1.07 (1
Logistic EuroSCORE, % 1.07 (1
EuroSCORE II, % 1.07 (1
Logistic EuroSCORE ≥40% 14.28 (5
EuroSCORE II ≥25% 6.16 (2
Preoperative LVEF <30% 4.31 (1
PAP (systolic), mmHg 1.03 (1
PAP (diastolic), mmHg 1.04 (1
Mean PAP, mmHg 1.04 (1
Preoperative inotropic drug support 3.51 (1
Preoperative IABP requirement 2.69 (1
Serum creatinine, μmol/L 1.00 (1
Acute renal failure 2.29 (0
Cardiogenic shock 3.37 (1
Salvage/Emergent mitral valve surgery 2.56 (1
MVR without preservation of the subvalvular apparatus 2.60 (1
No concomitant CABG 1.89 (0
Concomitant septal rupture 4.17 (0
Cardiopulmonary bypass time, min 1.01 (1
Intraoperative IABP requirement 2.99 (1
aModel 1; bModel 2; cModel 3; dModel 4; eModel 5.
CABG = coronary artery bypass grafting; CI = confidence interval; HR = hazard ratio;
MVR =mitral valve replacement; PAP = pulmonary artery pressure.(95% CI 1.03-1.09), Wald χ2 17.84, P < 0.001). The χ2
goodness-of-fit test (log likelihood ratio test) was signifi-
cant, indicating that this multivariate model is a good fit
(χ2 = 22.57, df = 1, P < 0.001).
Model 2
Multivariate Cox proportional-hazard regression analysis
with the EuroSCORE II as a continuous variable revealed
the EuroSCORE II as an independent predictor of overall
long-term survival (hazard ratio 1.06 (95% CI 1.02-1.09),
Wald χ2 9.68, P = 0.002). The χ2 goodness-of-fit test (log
likelihood ratio test) was significant, indicating that
this multivariate model is a good fit (χ2 = 10.44, df = 1,
P = 0.001).
Model 3
Multivariate Cox proportional-hazard regression analysis
with the logistic EuroSCORE ≥40% (categorical variable)
revealed the logistic EuroSCORE ≥40% as an independent
predictor of a lower overall long-term survival (hazard ra-
tio 16.69 (95% CI 4.23-65.84), Wald χ2 16.16, P < 0.001).
The χ2 goodness-of-fit test (log likelihood ratio test) was
significant, indicating that this multivariate model is a goodivariate and multivariate Cox proportional hazard
ysis Multivariate analysis
% CI P value HR 95% CI P value
.02-1.11) 0.003 − − −
.04-1.09) <0.001 1.06 (1.03-1.09) <0.001a
.04-1.10) <0.001 1.06 (1.02-1.09) 0.002b
.65-36.11) <0.001 16.69 (4.23-65.84) <0.001c
.81-13.48) <0.001 4.31 (1.67-11.14) 0.003d
.58-11.81) 0.004 − − −
.00-1.06) 0.069 − − −
.00-1.08) 0.071 − − −
.00-1.08) 0.059 − − −
.56-7.90) 0.002 6.27 (1.97-19.95) 0.002e
.25-5.77) 0.011 − − −
.00-1.01) 0.059 − − −
.96-5.48) 0.062 − − −
.35-8.41) 0.009 − − −
.08-6.06) 0.032 − − −
.23-5.46) 0.012 3.40 (1.19-9.69) 0.022e
.89-4.01) 0.098 − − −
.94-18.54) 0.061 − − −
.00-1.01) 0.026 − − −
.37-6.51) 0.006 − − −
IABP = intra-aortic balloon pump; LVEF = left ventricular ejection fraction;
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EuroSCORE ≥40% on overall long-term survival is shown
in a Kaplan-Meier survival curve (Figure 2A). Patients with
a logistic EuroSCORE ≥40% had a significantly lower mean
overall long-term survival (1.1 ± 0.6 years) compared to pa-
tients with a logistic EuroSCORE <40% (14.5 ± 1.4 years,
P < 0.001).
Model 4
Multivariate Cox proportional-hazard regression analysis
with the logistic EuroSCORE ≥25% (categorical variable)
revealed the logistic EuroSCORE ≥25% as an inde-
pendent predictor of a lower overall long-term survival
(hazard ratio 4.31 (95% CI 1.67-11.14), Wald χ2 9.12,
P = 0.003). The χ2 goodness-of-fit test (log likelihood
ratio test) was significant, indicating that this multi-
variate model is a good fit (χ2 = 10.64, df = 1, P = 0.001).
The influence of an EuroSCORE II ≥25% on overall
long-term survival is shown in a Kaplan-Meier sur-
vival curve (Figure 2B). Patients with an EuroSCORE
II ≥25% had a significantly lower mean overall long-term
survival (2.5 ± 1.2 years) compared to patients with an
EuroSCORE II <25% (14.1 ± 1.5 years, P < 0.001).
Model 5
After removal of the EuroSCOREs from the model, pre-
operative inotropic drug support (hazard ratio 6.27 (95%
CI 1.97-19.95), Wald χ2 9.64, P = 0.002) and MVR without
(partial or complete) preservation of the subvalvular ap-
paratus (SA) (hazard ratio 3.40 (95% CI 1.19-9.69), Wald
χ2 5.21, P = 0.022) were independent predictors of a lower
overall long-term survival. The χ2 goodness–of-fit test (log
likelihood ratio test) was significant, indicating that this
multivariate model is a good fit (χ2 = 14.06, df = 2,
P = 0.001). The influence of preoperative inotropic drugFigure 2 Kaplan-Meier actuarial overall long-term survival after mitra
Logistic EuroSCORE ≥40%. B: EuroSCORE II <25% vs. EuroSCORE ≥25%. ES II = Esupport and preservation of the SA on overall long-term
survival are shown in Kaplan-Meier survival curves
(Figure 3A-C). Patients who required preoperative ino-
tropic drug support had a significantly lower mean overall
long-term survival (6.2 ± 1.4 years) compared to patients
who did not require preoperative inotropic drug support
(14.7 ± 1.9 years, P = 0.001) (Figure 3A). Patients in which
the mitral valvular-ventricular continuity was preserved
(i.e. patients who underwent mitral valve repair or MVR
with (partial or complete) preservation of the SA) had a
significantly higher mean overall long-term survival
(12.4 ± 1.6 years) compared to patients who underwent
MVR without (partial or complete) preservation of the SA
(5.4 ± 2.1 years, P = 0.008) (Figure 3B). A survival com-
parison between patients who underwent MVR with
(n = 26) or without (partial or complete) preservation of
the SA (n = 14) also showed that MVR with (partial or
complete) preservation of the SA carries a significantly
higher mean overall long-term survival (11.4 ± 1.9 years)
than MVR without (partial or complete) preservation of
the SA (5.4 ± 2.1 years, P = 0.037) (Figure 3C). The type of
preservation (partial or complete preservation of the an-
terior, or posterior, or both mitral valve leaflets and the at-
tached SA) did not influence overall long-term survival.
Univariate and multivariate analyses showed that both
MVR and concomitant CABG did not predict overall
long-term survival. Patients who underwent MVR had a
mean overall long-term survival (9.2 ± 1.5 years) that did
not differ significantly from the mean overall long-term
survival in patients who underwent mitral valve repair
(14.0 ± 2.7 years, P = 0.111). Patients who did not undergo
concomitant CABG had a mean overall long-term survival
(8.1 ± 1.5 years) that did not differ significantly from the
mean overall long-term survival in patients who did
undergo concomitant CABG (12.7 ± 2.1 years, P = 0.089).l valve surgery for post-MI PMR. A: Logistic EuroSCORE <40% vs.
uroSCORE II; Log. ES = logistic EuroSCORE; Pts = patients; + = censored.
Figure 3 Kaplan-Meier actuarial overall long-term survival after
mitral valve surgery for post-MI PMR. A: No preoperative inotropic
drug support vs. preoperative inotropic drug support. B: Mitral valve
replacement with (partial or complete) preservation of the subvalvular
apparatus or mitral valve repair vs. mitral valve replacement without
(partial or complete) preservation of the subvalvular apparatus. C: Mitral
valve replacement with (partial or complete) preservation of the
subvalvular apparatus vs. mitral valve replacement without (partial
or complete) preservation of the subvalvular apparatus. MVP =mitral
valve plasty/repair; MVR =mitral valve replacement; SA = subvalvular
apparatus; Pts = patients; + = censored.
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Overall long-term survival for patients who underwent
mitral valve surgery for post-MI PMR was 71.9 ± 6.4%
after 1 year, 65.1 ± 6.9% after 5 years, 49.5 ± 7.6% after
10 years, 36.1 ± 8.0% after 15 years, and 23.7 ± 9.2% after
20 years in this study. Previous studies reported similar
overall long-term survival rates with 1 year-survival
ranging between 75% and 81% [14,15], 5 year-survival
ranging between 65% and 68% [14,15,17] and 10 year-
survival ranging between 32% and 56% [14,15,17].
Both the logistic EuroSCORE and EuroSCORE II were
strong independent predictors of overall long-term sur-
vival in this study. The logistic EuroSCORE was intro-
duced in 1999 and has proven its value as an important
risk-stratification model in cardiac surgery [20]. However,
the model was mainly designed for predicting in-hospital
mortality in CABG patients and its predictive power has
declined in recent years [21]. To more accurately predict
in-hospital mortality for patients undergoing a wider range
of cardiac surgical procedures the EuroSCORE II was in-
troduced in 2012 [22]. Although both EuroSCOREs were
not specifically designed for patients undergoing mitral
valve surgery for post-MI PMR or to assess long-term sur-
vival, these models can both be used as predictors of over-
all long-term survival in this setting. Both EuroSCOREs
contain items that were shown to be univariate predictors
(P < 0.10) of overall long-term survival in this study, such
as age, serum creatinine (incorporated in the creatinine
clearance in EuroSCORE II), LVEF, (systolic) pulmonary
artery pressure, preoperative inotropic drug support/
intra-aortic balloon pump (IABP) requirement/acute renal
failure (all incorporated in the “critical preoperative state”
item of both EuroSCOREs), emergency surgery, and post-
infarct septal rupture (only incorporated in the logistic
EuroSCORE as a separate item) (Table 4). A logistic
EuroSCORE ≥40% and an EuroSCORE II ≥25% are
both strong independent predictors of a worse overall
long-term survival after mitral valve surgery for post-
MI PMR (hazard ratio 16.69 and 4.31, respectively).
Preoperative haemodynamic instability and cardio-
genic shock following post-MI PMR may warrant the
use of inotropes and/or an IABP. However, stabilization
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deterioration and death are always imminent [2,4,7]. We
previously showed that intraoperative IABP requirement
was an independent predictor of in-hospital mortality after
mitral valve surgery for post-MI PMR [13], but it was not
an independent predictor of overall long-term mortality in
this study. Preoperative inotropic drug support was a
strong independent predictor of overall long-term survival
in this study. Mean overall long-term survival was signifi-
cantly lower in the group that required preoperative ino-
tropes (6.2 ± 1.4 years) compared to the group that did not
require preoperative inotropes (14.7 ± 1.9 years, P = 0.001).
Preoperative inotropic drug requirement may reflect re-
duced viability of myocardial reserve and a tendency to-
wards a faster postoperative deterioration of LVEF (and a
reduced survival) over time. However, relative preservation
of LVEF in most post-MI PMR patients requiring mitral
valve surgery [7,14] contradicts this explanation. Alterna-
tively, inotropic drugs themselves may also have deleteri-
ous effects, which may only become apparent after a
certain period of time. Several studies have shown that
inotropic stimulation of contractility in hibernating myo-
cardium without restoration of blood flow increases short-
term myocardial contractility at the expense of accelerated
apoptosis and further degeneration of myocardial function
[23-25]. These effects may also occur after short-term use
of inotropic drugs. However, the influence of (preoperative)
inotropic drug support on postoperative LVEF was not
assessed in this study.
MR secondary to partial or incomplete PMR with lim-
ited adjacent tissue damage is often amenable to a reli-
able repair, provided established repair techniques are
used and adjacent tissue is not friable [7,8,10-13,17]. All
10 repair patients in this study experienced partial or
incomplete PMR. Complete post-MI PMR generally
requires MVR because of friable infarcted tissue
[7,11,13,15,17]. In this study mean overall long-term
survival in the repair group (14.0 ± 2.7 years) did not
differ significantly from the mean overall long-term sur-
vival in the replacement group (9.2 ± 1.5 years, P = 0.111).
A major finding in this study is that (partial or complete)
preservation of the SA in patients undergoing mitral valve
surgery for post-MI PMR independently predicts and sig-
nificantly improves overall long-term survival. Patients in
which mitral valvular-ventricular continuity or papillary
muscle-annular continuity was preserved (i.e. patients
who underwent mitral valve repair or MVR with (partial
or complete) preservation of the SA) had a significantly
higher mean overall long-term survival (12.4 ± 1.6 years)
compared to patients who underwent MVR without
(partial or complete) preservation of the SA (5.4 ± 2.1 years,
P = 0.008). A separate survival comparison in the replace-
ment group also showed that mean overall long-term sur-
vival is significantly higher after MVR with (partial orcomplete) preservation of the SA (11.4 ± 1.9 years) com-
pared to MVR without (partial or complete) preservation
of the SA (5.4 ± 2.1 years, P = 0.037). In general it has been
shown that MVR with preservation of the SA maintains
postoperative LV contractile function and improves out-
come [9]. This study shows that MVR with (partial or
complete) preservation of the SA improves overall long-
term survival specifically for patients with post-MI PMR.
Several techniques are available for preservation of the
SA in MVR [26]. The type of preservation (partial or
complete preservation of the anterior, or posterior, or
both mitral valve leaflets and the attached SA) did not
influence overall long-term survival in this study. Al-
though we prefer to preserve as much of the SA in
MVR as possible to maintain optimal valvular-ventricular
(or papillary muscle-annular) continuity [27], resection of
the anterior mitral valve leaflet and the attached SA are
frequently required to facilitate implantation of a suitably
sized valve, to prevent interference of the SA with the
prosthetic valve mechanism, and to prevent left ventricu-
lar outflow tract obstruction [26].
The relative importance of concomitant CABG in the
setting of mitral valve surgery for post-MI PMR remains
unclear. It has been shown that concomitant CABG can
improve immediate [7,16] and long-term survival [7]
after post-MI PMR, but a more recent study was unable
to corroborate those findings for long-term survival [17].
Concomitant CABG was not a predictor of overall long-
term survival in this study. Mean overall long-term sur-
vival was 12.7 ± 2.1 years in the concomitant CABG
group and 8.1 ± 1.5 years in the no concomitant CABG
group, P = 0.089. Revascularization of any kind (pre-
operative PCI (balloon angioplasty with or without
stenting) (n = 10), concomitant CABG (n = 20), or both
(n = 4)) also did not improve overall long-term survival.
Mean overall long-term survival was 11.8 ± 1.8 years in
the revascularization group and 7.8 ± 1.9 years in the no
revascularization group, P = 0.143. At this point, there
are no randomized studies to determine the relative
importance of concomitant CABG or hybrid PCI ap-
proaches in the setting of post-MI PMR. Results from the
SHOCK (should we emergently revascularize occluded
coronaries in cardiogenic shock) trial did show improved
long-term survival with early revascularization for car-
diogenic shock complicating MI [28], but patients with
PMR were excluded in this trial. Concomitant CABG
may improve postoperative LV function and survival in
the setting of post-MI PMR, but these potential benefits
have to be weighed against the consequences of prolong-
ing the duration of cardiopulmonary bypass.
A propensity-matched case–control study recently
showed that life expectancy may return to normal (i.e. to
the life expectancy of patients with a similar MI, but with-
out PMR) for operative survivors (patients who survived
Bouma et al. Journal of Cardiothoracic Surgery  (2015) 10:11 Page 9 of 10the first 30 days after surgery) [17]. Five-year survival
for patients with a similar MI but no PMR was 79 ± 4%;
10-year survival was 55 ± 6% [17]. After recalculation re-
sults from this study support those findings with a 5-year
survival rate of 86 ± 6% and a 10-year survival rate of
65 ± 9% for operative survivors. Return to normal life ex-
pectancy provides an additional argument for prompt diag-
nosis and aggressive surgical treatment of post-MI PMR.
Even though this is one of the largest studies on mitral
valve surgery for post-MI PMR, the number of patients
is still relatively small. Other limitations include the long
time frame and the non-randomized retrospective de-
sign. Larger multicenter (preferably randomized) studies
are required to more accurately identify independent
predictors of short- and long-term outcome and to de-
termine potential outcome benefits of mitral valve repair
over replacement for post-MI PMR. However, such stud-
ies would be very difficult to conduct and would prob-
ably face major ethical issues.
Conclusions
Our findings indicate that logistic EuroSCORE ≥40%,
EuroSCORE II ≥25%, preoperative inotropic drug sup-
port and MVR without (partial or complete) preserva-
tion of the subvalvular apparatus are strong independent
predictors of a lower overall long-term survival in pa-
tients undergoing mitral valve surgery for post-MI PMR.
Whenever possible, the subvalvular apparatus should be
preserved in these patients.
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